PRA Health Sciences Inc (PRAH) Position Increased by First Bank & Trust

First Bank & Trust increased its holdings in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 30.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,259 shares of the medical research company’s stock after buying an additional 752 shares during the quarter. First Bank & Trust’s holdings in PRA Health Sciences were worth $297,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. BlackRock Inc. lifted its position in shares of PRA Health Sciences by 28.2% during the 2nd quarter. BlackRock Inc. now owns 3,662,954 shares of the medical research company’s stock worth $274,759,000 after buying an additional 805,573 shares during the last quarter. Capital Research Global Investors raised its position in PRA Health Sciences by 318.3% in the second quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock valued at $163,172,000 after purchasing an additional 1,655,336 shares during the last quarter. Wells Fargo & Company MN raised its position in PRA Health Sciences by 55.8% in the third quarter. Wells Fargo & Company MN now owns 1,207,069 shares of the medical research company’s stock valued at $91,943,000 after purchasing an additional 432,449 shares during the last quarter. Russell Investments Group Ltd. raised its position in PRA Health Sciences by 3.4% in the third quarter. Russell Investments Group Ltd. now owns 915,111 shares of the medical research company’s stock valued at $69,704,000 after purchasing an additional 29,771 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in PRA Health Sciences by 5.7% in the third quarter. Ameriprise Financial Inc. now owns 834,034 shares of the medical research company’s stock valued at $63,528,000 after purchasing an additional 45,227 shares during the last quarter. Institutional investors and hedge funds own 98.23% of the company’s stock.

PRAH has been the subject of several research reports. BidaskClub upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th. Robert W. Baird reiterated a “buy” rating and issued a $88.00 target price on shares of PRA Health Sciences in a research report on Monday, October 9th. Mizuho initiated coverage on PRA Health Sciences in a research report on Thursday, September 21st. They issued a “buy” rating and a $82.00 target price for the company. Jefferies Group reiterated a “buy” rating and issued a $95.00 target price on shares of PRA Health Sciences in a research report on Thursday, October 26th. Finally, KeyCorp reiterated a “buy” rating and issued a $93.00 target price (up from $86.00) on shares of PRA Health Sciences in a research report on Monday, October 30th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. PRA Health Sciences presently has a consensus rating of “Buy” and a consensus target price of $91.85.

Shares of PRA Health Sciences Inc (NASDAQ:PRAH) traded up $1.73 during mid-day trading on Thursday, hitting $92.10. The stock had a trading volume of 327,300 shares, compared to its average volume of 438,718. The firm has a market capitalization of $5,850.00, a PE ratio of 51.74, a price-to-earnings-growth ratio of 1.26 and a beta of 0.41. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38. PRA Health Sciences Inc has a 12 month low of $54.08 and a 12 month high of $92.84.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.03. The company had revenue of $494.55 million during the quarter, compared to analysts’ expectations of $477.89 million. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The business’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.64 earnings per share. equities analysts forecast that PRA Health Sciences Inc will post 3.2 earnings per share for the current year.

In other news, Director Matthew P. Young sold 5,115 shares of the stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $79.90, for a total value of $408,688.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David W. Dockhorn sold 72,850 shares of the stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $90.83, for a total value of $6,616,965.50. The disclosure for this sale can be found here. In the last three months, insiders sold 150,815 shares of company stock valued at $13,642,620. Insiders own 2.10% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3144401/pra-health-sciences-inc-prah-position-increased-by-first-bank-trust.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.